REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
16/06/2025
Voltar para busca
Dado oficial do USPTO
QUELL
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Snapshot rápido
QUELL
ST13
US500000088372290Classe
5, 40, 42, 44
Pedido
88372290
Registro
6077717
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
32
Atualização mais recente
17/06/2025
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
5, 40, 42, 44
Data de depósito
04/04/2019
Data de registro
16/06/2020
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
16/06/2020
Última transação
17/06/2025
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Fundamento do pedido
Intent to use, Foreign priority
Código do desenho
4
Tipo de titular
99
Localização do titular
London, GB
Examinador
BAYLISS,HUNTER A
Unidade examinadora
M40
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
Quell Therapeutics Limited
Representantes
Steven T. Shelton SHELTON IP
Classificação técnica
Classes Nice
Classe 5Classe 40Classe 42Classe 44
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Pharmaceutical and biological preparations for diagnosticmedicaltherapeuticprophylactic use for inducing tolerance to a transplant and for treatingpreventing or ameliorating transplant rejectionGraft-versus-Host Disease (GvHD)autoimmune and allergic diseaseundesired inflammation and inflammatory diseasefor promoting tissue repair and regeneration; veterinary preparations for diagnosticmedicaltherapeuticprophylactic use for inducing tolerance to a transplant and for treatingpreventing or ameliorating transplant rejectionGraft-versus-Host Disease (GvHD)autoimmune and allergic diseaseundesired inflammation and inflammatory diseasefor promoting tissue repair and regeneration; preparations for cell therapypreparations comprising T cells having an immunosuppressive phenotype; preparations for gene therapy; pharmaceuticalmedicalclinical preparations for use in treatmentamelioration and prophylaxis of immune system related diseases and disorders; preparations for therapies to modulate the immune system for inducing tolerance to a transplant and for treatingpreventing or ameliorating transplant rejectionGraft-versus-Host Disease (GvHD)autoimmune and allergic diseaseundesired inflammation and inflammatory diseasefor promoting tissue repair and regeneration; preparations for therapies for autoimmune conditions and immunological disorders; cancer preparationschimeric antigen receptors and therapeutic preparations thereof for inducing tolerance to a transplant and for treatingpreventing or ameliorating transplant rejectionGraft-versus-Host Disease (GvHD)autoimmune and allergic diseaseundesired inflammation and inflammatory diseasefor promoting tissue repair and regeneration; diagnostic kits consisting of monoclonal antibodies for use in disease testing and for inducing tolerance to a transplant and for treatingpreventing or ameliorating transplant rejectionGraft-versus-Host Disease (GvHD)autoimmune and allergic diseaseundesired inflammation and inflammatory diseasefor promoting tissue repair and regeneration; preparations for therapeutic delivery of nucleic acids for inducing tolerance to a transplant and for treatingpreventing or ameliorating transplant rejectionGraft-versus-Host Disease (GvHD)autoimmune and allergic diseaseundesired inflammation and inflammatory diseasefor promoting tissue repair and regeneration; viral or nucleic acid vectors for therapeutic or prophylactic purposes and preparations containing such vectors for inducing tolerance to a transplant and for treatingpreventing or ameliorating transplant rejectionGraft-versus-Host Disease (GvHD)autoimmune and allergic diseaseundesired inflammation and inflammatory diseasefor promoting tissue repair and regeneration; preparations for genetically modifying human and animal cells for diagnostic and medical purposes; preparations of blood or cells extracted from humans or animals which have been adapted for therapeutic purposes; none of the foregoing having any relation to pain treatment or management
Classe 40
Manufacturing and processing pharmaceuticals for others; manufacturing and processing biologicalbiotechnological and biopharmaceutical preparations for others; processing of biological tissuebloodcellgenetic material for others; production and manufacture of viral vectors for others; production and manufacture of gene therapy products for others; custom manufacture of pharmaceutical and biological preparations for others; none of the foregoing having any relation to pain treatment or management
Classe 42
advisory services relating to gene therapy and design; Scientific and technological servicesresearch and design in the field of T cells with an immunosuppressive phenotype and transplant rejectionGraft-versus-Host Disease (GvHD)autoimmune and allergic diseaseundesired inflammation and inflammatory diseasefor promoting tissue repair and regeneration; industrial analysis and research in the field of cell therapy; medical and veterinary research services in the field of the manipulation of cells within a laboratory or research facility to enable the cells to be used for therapeutic purposes; scientific research in the development of new therapies in the field of autoimmuneimmunological disorders and to modulate the immune system; scientific research in human and animal cell therapy; scientific research in human and animal gene therapy; scientific research into vectors and preparations for manipulating and adapting human and animal cells; scientific and technological servicesdesign in the field of cell therapy; none of the foregoing having any relation to pain treatment or management
Classe 44
Medical services; medical services in the field of immunology; medical services in the field of surgery; medical services in the field of autoimmune diseases and conditions; medical servicesin the field oftissue transplant surgery; collection and preservation of biological tissuebloodcells and genetic materials; medical diagnosis of transplant rejectionGraft-versus-Host Disease (GvHD)autoimmune and allergic diseaseundesired inflammation and inflammatory diseasefor promoting tissue repair and regeneration; Medical treatment of transplant rejectionGraft-versus-Host Disease (GvHD)autoimmune and allergic diseaseundesired inflammation and inflammatory diseasefor promoting tissue repair and regeneration; providing information and data for diagnosis and medical treatment of transplant rejectionGraft-versus-Host Disease (GvHD)autoimmune and allergic diseaseundesired inflammation and inflammatory diseasefor promoting tissue repair and regeneration; gene and nucleic acid delivery or modification for therapeutic purposes; medical treatmentadministering cell or gene therapies; advisory services in the field of health as it relates to cell or gene therapy; medical advisory services relating to cell or gene therapy; none of the foregoing having any relation to pain treatment or management
Publicações
Histórico de despachos e eventos da marca no USPTO.
32 publicações encontradas
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
25/01/2023
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
25/01/2023
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
25/01/2023
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
25/01/2023
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
25/01/2023
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
25/01/2023
R.PR
REGISTERED-PRINCIPAL REGISTER
16/06/2020
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
31/03/2020
PUBO
PUBLISHED FOR OPPOSITION
31/03/2020
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
11/03/2020
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
25/02/2020
XAEC
EXAMINER'S AMENDMENT ENTERED
25/02/2020
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
25/02/2020
GNEA
EXAMINERS AMENDMENT E-MAILED
25/02/2020
CNEA
EXAMINERS AMENDMENT -WRITTEN
25/02/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
13/02/2020
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
13/02/2020
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
13/02/2020
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
23/01/2020
GNRT
NON-FINAL ACTION E-MAILED
23/01/2020
CNRT
NON-FINAL ACTION WRITTEN
23/01/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
30/12/2019
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
30/12/2019
ALIE
ASSIGNED TO LIE
30/12/2019
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
09/12/2019
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
24/06/2019
GNRT
NON-FINAL ACTION E-MAILED
24/06/2019
CNRT
NON-FINAL ACTION WRITTEN
24/06/2019
DOCK
ASSIGNED TO EXAMINER
14/06/2019
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
22/04/2019
NWAP
NEW APPLICATION ENTERED
08/04/2019
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace QUELL ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.